Rushdia Yusuf is an Oncology physician affiliated with Merck & Co.. OpenAlex indexes 60 publications with 3,400 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Grb 740, 55 Fruit Street
Mass General Hospital
Boston, MA 02114
Telephone
617-726-2000Provider last certified this registry record 21 Oct 2024.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy
Leukemia & lymphoma/Leukemia and lymphoma
2025 - waveLINE-010: Zilovertamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Lubiniecki, MD
Merck & Co.
Luther Clark, MD
Merck & Co.
Alfred Saah, MD
Merck & Co.
Keith Kaufman, MD
Merck & Co.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”